ClinicalTrials.gg

Program

human retinal progenitor cells

Its studies are mostly in Retinitis Pigmentosa, led by jCyte.

Furthest: phase 2, since Dec 16, 20144 company-led studies, 1 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
jCyte41 open or runningphase 2since Dec 16, 2014Dec 16, 2014Dec 2026phase 2 · NCT06912633

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 16, 2014First study: phase 2 study in Retinitis PigmentosaFirst studyNCT02320812 · 28 enrolled · United States
  2. Mar 2, 2017Phase 2 study in Retinitis PigmentosaNCT03073733 · 84 enrolled · United States
  3. Oct 16, 2020Phase 2 study in Retinitis PigmentosaNCT04604899 · 30 enrolled · United States
  4. Mar 26, 2025Phase 2 study in Retinitis PigmentosaNCT06912633 · 31 enrolled · United States

Ahead

  1. Dec 2026Primary completion: phase 2 study in Retinitis PigmentosaNCT06912633

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06912633Retinitis Pigmentosa · United States2Active, not recruitingDec 202631
NCT04604899Retinitis Pigmentosa · United States2CompletedMar 22, 202230
NCT03073733Retinitis Pigmentosa · United States2CompletedNov 13, 202084
NCT02320812Retinitis Pigmentosa · United States2CompletedJul 19, 201728

How it is read

Names in the registry

  • “human retinal progenitor cells”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.